Search

Displaying results 1681 - 1690 of 4262 in total
  1. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    The product does not remain permanently engrafted, instead being replaced by the patient's own cells over time, which can reduce or even eliminate the need for autografting. … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound

  2. Drug

    Fludrocortisone

    go.drugbank.com/drugs/DB00687
    ApprovedInvestigational

    [A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position

  3. Drug

    Mineral oil

    go.drugbank.com/drugs/DB11057
    ApprovedInvestigationalVet approved

    During the modern refining process, aromatics are reduced by solvent extraction, catalytic hydrotreating, or hydrocracking. … Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined.

  4. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … [FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.

  5. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379] … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

  6. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    [A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an

  7. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.

  8. Drug

    Human papillomavirus type 31 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10310
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 31 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

  9. Drug

    Perboric acid

    go.drugbank.com/drugs/DB13235
    Approved

    [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764] … [F66] Perboric acid in the form of sodium perborate is approved by Health Canada since 2004 to be used as a disinfectant of medical instruments.

  10. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    Phenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United … The primary goal of lifelong treatment of PKU, as recommended by the American College of Medical Genetics and Genomics (ACMG) guidelines, is to maintain blood Phe concentration in the range of 120 µmol